Position in VCEL
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$1,601
+$443 QoQ
Shares Held
36
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#292
of 315 holders
Holding Since
Dec 2025
3 quarters on record
Common Shares in VCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Strive Financial Group ,LLC holds $492,780 across 13 Biotechnology names. VCEL ranks #7 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
525 | $260,783 | |
| 2 | GNLX |
GENELUX Corp
|
41,437 | $124,725 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
312 | $76,368 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
230 | $12,544 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
235 | $8,316 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11 | $6,858 | |
| 7 | VCEL |
Vericel Corp
This page
|
36 | $1,601 | |
| 8 | CNTX |
Context Therapeutics Inc.
|
1,700 | $941 |
All Filings in VCEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,601 | 36 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $1,158 | 36 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,296 | 36 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||